Docetaxel-Based Chemotherapy in Elderly Patients (Age 75 and Older) with Castration-Resistant Prostate Cancer

European Urology

Volumn 55, Issue 6, 2009, Pages 1368-1376

  Italiano, Antoine ^a,b   Ortholan, Cécile ^b   Oudard, Stéphane ^c   Pouessel, Damien ^d   Gravis, Gwenaëlle ^e   Beuzeboc, Philippe ^f   Bompas, Emmanuelle ^g   Fléchon, Aude ^h   Joly, Florence ⁱ   Ferrero, Jean Marc ^b   Fizazi, Karim ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d CENTRE VAL D AURELLE   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f INSTITUT CURIE   (France)

^g CENTRE RENÉ GAUDUCHEAU   (France)

^h CENTRE LÉON BÉRARD   (France)

ⁱ CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Castration resistant; Docetaxel; Elderly; Prostate cancer; Weekly docetaxel

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; MITOXANTRONE; NAVELBINE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; STRONTIUM 89; VINBLASTINE;

AGED; AGING; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CASTRATION; CHOLESTASIS; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAIL; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RASH; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VISCERAL METASTASIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; GERIATRIC ASSESSMENT; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 65049085711     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.07.078     Document Type: Article

References (35)

1. SEER Cancer Statistics Review 1975-2004: tables I-10 and I-12. National Cancer Institute Web site. Available at http://seer.cancer.gov/csr/1975_2004/results_merged/topic_age_dist.pdf.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
3. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
4. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
5. Tabernero J., Climent M.A., Lluch A., et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15 (2004) 1358-1365
6. Camps C., Massuti B., Jiménez A., et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17 (2006) 467-472
7. Gridelli C., Gallo C., Di Maio M., et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 91 (2004) 1996-2004
8. Gervais R., Ducolone A., Breton J.L., et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16 (2005) 90-96
9. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
10. Thuret R., Massard C., Gross-Goupil M., et al. The post-chemotherapy PSA surge syndrome. Ann Oncol 19 (2008) 1308-1311
11. Coebergh J.W., Janssen-Heijnen M.L., Post P.N., et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of the Netherlands in 1993-1996. J Clin Epidemiol 52 (1999) 1131-1136
12. Berthold D.R., Pond G.R., Soban F., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 (2008) 242-245
13. Wildiers H., and Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 30 (2004) 333-342
14. Crawford J., Dale D.C., and Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100 (2004) 228-237
15. Ten Tije A.J., Verweij J., Carducci M.A., et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23 (2005) 1070-1077
16. Minami H., Ohe Y., Niho S., et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: Why is toxicity increased in elderly patients?. J Clin Oncol 22 (2004) 2901-2908
17. Hurria A., Fleming M.T., Baker S.D., et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 12 (2006) 6100-6105
18. Shayne M., and Lichtman M.A. Hematology in older persons. In: Lichtman M.A., Beutler E., Kipps T.J., et al. (Eds). Williams Hematology. 7th ed. (2006), McGraw-Hill, New York, NY
19. Beer T.M., Berry W., Wersinger E.M., and Bland L.B. Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. Clin Prostate Cancer 2 (2003) 167-172
20. Mandrekar S.J., Northfelt D.W., Schild S.E., et al. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. J Thorac Oncol 1 (2006) 556-563
21. Freyer G., Geay J.F., Touzet S., et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16 (2005) 1795-1800
22. Beer T.M., Pierce W.C., Lowe B.A., and Henner W.D. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12 (2001) 1273-1279
23. Friedland D., Cohen J., Miller Jr. R., et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26 Suppl 17 (1999) 19-23
24. Petrylak D.P., Macarthur R., O'Connor J., et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 26 Suppl 17 (1999) 28-33
25. Fosså S.D., Jacobsen A.-B., Ginman C., et al. Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol 52 (2007) 1691-1699
26. Savarese D.M., Halabi S., Hars V., et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 19 (2001) 2509-2516
27. Petrylak D.P., Macarthur R.B., O'Connor J., et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17 (1999) 958-967
28. Smaletz O., Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20 (2002) 3972-3982
29. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
30. Armstrong A.J., Garrett-Mayer E.S., Yang Y.C., et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13 (2007) 6396-6403
31. Bamias A., Bozas G., Antoniou N., et al. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol 53 (2008) 323-332
32. Extermann M., and Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25 (2007) 1824-1831
33. Maas H.A., Janssen-Heijnen M.L., Olde Rikkert M.G., and Machteld Wymenga A.N. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer 43 (2007) 2161-2169
34. Wedding U., Ködding D., Pientka L., et al. Physicians' judgement and comprehensive geriatric assessment (CGA) select different patients as fit for chemotherapy. Crit Rev Oncol Hematol 64 (2007) 1-9
35. Droz J.P., Balducci L., Bolla M., et al. SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men. Urology 70 (2007) 311-312 Abstract POS-03.126